| Aug 6 |
Aquestive Therapeutics GAAP EPS of -$0.03 beats by $0.09, revenue of $20.09M beats by $7.71M
|
| Aug 6 |
Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Aug 5 |
Aquestive Therapeutics Q2 2024 Earnings Preview
|
| Jul 30 |
Institutions profited after Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) market cap rose US$72m last week but retail investors profited the most
|
| Jul 25 |
Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
|
| Jul 23 |
Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET
|
| Jul 11 |
New Strong Sell Stocks for July 11th
|
| Jun 27 |
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
|
| Jun 25 |
Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows
|
| Jun 25 |
Aquestive gains after initial data for allergy candidate
|
